Foundayo (Orforglipron) for Weight Loss: How It Compares to Wegovy, Zepbound, and Other Options

Medically Reviewed by

Jaclyn P. Leyson-Azuela, RMT, MD, MPH

DoctorAdam Medical Review • Weight Loss Treatment Guide

Oral Semaglutide

Daily oral GLP-1 option

From $129 Get Started

Semaglutide Injection

Weekly GLP-1 injection

From $129 Get Started

Tirzepatide Tablets

Oral treatment option

From $199 Get Started

Tirzepatide Injection

Weekly dual-action support

From $229 Get Started

What Is Foundayo (Orforglipron)?

Foundayo, known by its generic name orforglipron, is a once-daily oral pill developed by Eli Lilly. In April 2026, the U.S. Food and Drug Administration (FDA) approved it for adults with obesity, or for adults who are overweight and have at least one weight-related health condition , such as high blood pressure, high cholesterol, or sleep apnea. The FDA made its decision in just 50 days, the fastest approval of a new kind of drug since 2002.

What makes Foundayo different from most other weight loss medications in its class is how it works on a biological level. It belongs to a group called GLP-1 receptor agonists,  medications that mimic a natural hormone in the body that helps regulate appetite and blood sugar. While most GLP-1 medications are either injections or pills that require strict fasting before and after taking them, Foundayo is a small-molecule pill that can be taken anytime during the day, with or without food or water. For many people, that kind of flexibility can make a real difference in sticking to their treatment.

Doctor-Guided Weight Loss

Compare Your Options With a Licensed Provider

Start with a short online visit and get matched with a personalized weight loss plan based on your goals, preferences, and medical history.

Start Online Visit

How Much Weight Can Foundayo Help People Lose?

In the Phase 3 ATTAIN-1 clinical trial, a large, rigorous study involving over 2,000  participants, people taking the highest dose of Foundayo lost an average of about 5.1 -- 9.6% of their baseline body weight over 72 weeks. Nearly 60% of participants on the highest dose lost at least 10% of their body weight, and close to 40% lost at least 15%. Beyond weight loss, the trial also found improvements in blood pressure, cholesterol, and inflammation levels, signs that the medication may benefit overall heart health, not just the number on the scale.

In a separate trial called ATTAIN-MAINTAIN, people who had been taking injectable GLP-1 medications like Wegovy or Zepbound were switched to Foundayo. They maintained nearly all of the weight they had previously lost, showing that the pill may also work well as a longer-term continuation option for those who prefer to move away from injections.

How Does It Compare to Other Weight Loss Medications?

Wegovy (Semaglutide) — Weekly Injection

Wegovy, made by Novo Nordisk, is one of the most well-known GLP-1 weight loss medications. It is given as a once-weekly injection under the skin and was FDA-approved in 2021. In the STEP 5 clinical trial, participants lost an average of 15.2% of their body weight over two years. A newer pill form of Wegovy was also approved by the FDA in December 2025, though it requires specific food and water restrictions around dosing time.

Wegovy generally produces slightly more weight loss on average than Foundayo (about 15% versus 12.4%). However, for people who prefer a pill with fewer restrictions, or those who are uncomfortable with injections, Foundayo may be a more practical fit.

Zepbound (Tirzepatide) — Weekly Injection

Zepbound, also made by Eli Lilly, is currently the most effective FDA-approved medication for weight loss on the market. It works differently from Foundayo — it targets not one but two hormones (GIP and GLP-1), which may explain why it produces greater results. In a direct head-to-head trial (SURMOUNT-5) published in The New England Journal of Medicine, participants on Zepbound lost an average of 20.2% of their body weight, compared to 13.7% for those on Wegovy, a 47% greater relative weight loss.

In clinical trials (SURMOUNT-1), participants on the highest dose of Zepbound lost an average of 22.5% of their body weight over 72 weeks. That is significantly more than what Foundayo achieves. For someone whose doctor determines that maximum weight loss is the priority, Zepbound may be the stronger option, though it is only available as a weekly injection and comes with a higher out-of-pocket cost.

Qsymia and Contrave — Older Oral Medications

Before GLP-1 medications arrived, two combination pills were the go-to oral options: Qsymia (phentermine/topiramate) and Contrave (naltrexone/bupropion).

Qsymia, approved in 2012, works by suppressing appetite through stimulant-like effects. Clinical data shows it produces roughly 7–9% body weight reduction. Contrave works by targeting the brain's reward and craving pathways, producing about 4–5% weight loss. Both are available as pills and tend to be more affordable.

However, these older medications carry more serious safety concerns. Qsymia is known to cause birth defects and can only be prescribed through a special safety program. Contrave carries a black box warning, the most serious FDA warning, related to risk of suicidal thoughts and behavior. These are not small concerns, and patients should discuss them openly with a doctor. That said, for people who cannot access newer medications due to cost or insurance barriers, these may still be viable options under careful medical supervision.

Side-by-Side at a Glance

What About Side Effects?

All weight loss medications come with side effects, and it is completely normal to feel nervous about that. For Foundayo, the most commonly reported side effects in clinical trials were gastrointestinal (GI), meaning related to the digestive system. These include:

• Nausea
• Constipation
• Vomiting
• Diarrhea
• Burping
• Stomach pain or indigestion

A research review noted that nausea rates with orforglipron were among the highest seen in oral GLP-1 medications, though most GI side effects were described as mild to moderate in severity and consistent with the broader GLP-1 class. These side effects tend to be most noticeable early in treatment and may ease as the body adjusts.

For comparison, injectable GLP-1 medications like Wegovy and Zepbound share similar GI side effects. The older medications Qsymia and Contrave carry their own distinct risks, including the serious warnings mentioned above.

Who Is Foundayo Right For?

No single medication works the same way for every person, and weight loss treatment is deeply personal. Foundayo may be worth discussing with a doctor if a patient:

• Prefers a daily pill over weekly injections
• Has had difficulty with the fasting requirements of other oral GLP-1 medications
• Has already achieved weight loss with injectable GLP-1s and is looking for a convenient oral alternative to maintain progress
• Has obesity or is overweight with a related health condition like high blood pressure or high cholesterol

For those who need the greatest amount of weight loss, or who are already well-managed on an injectable GLP-1, a doctor might recommend staying with or switching to Zepbound or Wegovy instead. For people with tight budgets and limited insurance, an older medication like Qsymia may remain a practical , though more limited, first step.

At Doctor Adam, we value the safety of our patients. Therefore, we put your health on top of our priority list. We tailor advice according to your needs and lifestyle, while meeting your preferences.

Final Thoughts

Starting a conversation with a doctor about weight loss medication can feel vulnerable. It is okay to bring questions, worries, and even hesitations. Wanting to understand options before committing to anything is not just reasonable, it is wise. The fact that patients now have more choices, including a pill that does not require injections or fasting restrictions, reflects real progress in making care more accessible and manageable for more people.

Foundayo is not a magic pill, and no weight loss medication works without lifestyle changes alongside it. But for many adults who have struggled for years, it represents a genuine new option, one backed by clinical evidence, approved by the FDA, and designed to fit into everyday life.

Frequently Asked Questions

Medically Reviewed by

Jaclyn P. Leyson-Azuela, RMT, MD, MPH, is a physician, medical writer, and researcher with a strong background in public health, clinical medicine, and academic instruction. She has served as an Assistant Professor teaching core medical sciences, a Doctor-to-the-Barrio delivering frontline care in underserved communities, and a COVID-19 facility manager during the pandemic.